Trabectedin for advanced or metastatic soft tissue sarcoma .

Complementario al post del dia 10 de Mayo :

Yondelis STS , Informe del London New Drugs Group . 9 Mayo 2008 .

Yondelis, Fase III de J&J en Sarcomas , espera completarla en Mayo 2009 .

A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment .

Verified by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., April 2008

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer .

Verified by National Cancer Institute (NCI), May 2008

Deforolimus (AP23573) in Treatment of Sarcoma de Ariad en Fase III , ensayo que espera Completar en Marzo 2011 .

Una Fase III que inicio hace unos meses y que va a un buen ritmo .... Se trata de un Farmaco en el que hay grandes esperanzas puestas para un tipo de Cancer ( Sarcoma )que pocas Farmaceuticas apuestan por invertir en el :
The purpose of this study is to determine whether maintenance therapy with oral AP23573 (deforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo.

Hallan la proteína culpable del cáncer de pulmón por tabaquismo ,llamada FANCD2, según el el equipo del Instituto del Cáncer de la Oregon Health ...